Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
吉西他滨联合或不联合ATR抑制剂Berzosertib治疗铂类耐药卵巢癌的随机II期研究:最终总生存期和生物标志物分析
期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO.23.00635
Konstantinopoulos, Panagiotis A; Cheng, Su-Chun; Lee, Elizabeth K; da Costa, Alexandre André B A; Gulhan, Doga; Wahner Hendrickson, Andrea E; Kochupurakkal, Bose; Kolin, David L; Kohn, Elise C; Liu, Joyce F; Penson, Richard T; Stover, Elizabeth H; Curtis, Jennifer; Sawyer, Hannah; Polak, Madeline; Chowdhury, Dipanjan; D'Andrea, Alan D; Färkkilä, Anniina; Shapiro, Geoffrey I; Matulonis, Ursula A